RecurX Bio, Inc
Recur X Bio - Summary RecurX Bio's phenotypic microfluidic assay captures the deadly cell sub population responsible for cancer metastasis and rapid spread. Our test is used to Determine how serious is the patients disease, Reveal how well the Standard of Care treatment will work Uncover better existing drugs Discover new cancer drugs Prevent unnecessary side effects from drugs that do not work We are planning to go to market with tests for Glioblastoma first followed likely by metastatic brain cancer and breast cancer We are seeking to collaborate with pharmaceutical companies to provide more effective drug development. Approximately 97%+ of cancer drugs fail in development and clinical trials, in part because laboratory models do not accurately represent what happens in the body during metastasis. Better technology is necessary to bring much needed drugs to market. New drug discovery can potentially occur faster, less expensively and with greater success using RecurX Bio's technology. Our technology is designed to screen and select drug candidates for preclinical and clinical testing and to identify unique drugable targets in the most deadly cells captured by our technology. Discovery, translation and clinical research in breast cancer and glioblastoma is being carried ourt in the labs of Prof Kostas Konstantopoulos and Dr Alfredo Quinones - Hinojosa at Johns Hopkins and Mayo Clinic respectively with $9m in NIH funding to date and more to come. Two Nature Biotechnology publications have resulted and 3 patents.
RecurX Bio, Inc
Recur X Bio - Summary RecurX Bio's phenotypic microfluidic assay captures the deadly cell sub population responsible for cancer metastasis and rapid spread. Our test is used to Determine how serious is the patients disease, Reveal how well the Standard of Care treatment will work Uncover better existing drugs Discover new cancer drugs Prevent unnecessary side effects from drugs that do not work We are planning to go to market with tests for Glioblastoma first followed likely by metastatic brain cancer and breast cancer We are seeking to collaborate with pharmaceutical companies to provide more effective drug development. Approximately 97%+ of cancer drugs fail in development and clinical trials, in part because laboratory models do not accurately represent what happens in the body during metastasis. Better technology is necessary to bring much needed drugs to market. New drug discovery can potentially occur faster, less expensively and with greater success using RecurX Bio's technology. Our technology is designed to screen and select drug candidates for preclinical and clinical testing and to identify unique drugable targets in the most deadly cells captured by our technology. Discovery, translation and clinical research in breast cancer and glioblastoma is being carried ourt in the labs of Prof Kostas Konstantopoulos and Dr Alfredo Quinones - Hinojosa at Johns Hopkins and Mayo Clinic respectively with $9m in NIH funding to date and more to come. Two Nature Biotechnology publications have resulted and 3 patents.
recurxbio.com
Baltimore, MD, US
Details
Year founded
2020
Revenue
1M-5M
Employees
1-10
Number of locations
1
NAICS
3391
SIC
3841
Products & Services
Outlines the company's specialized services and operational strengths.
- Cancer drugs selection
- Personalized information for oncologists
- Phenotypic microfluidic assay
- Contact us in order to access
Equipment
Provides a detailed list of machinery and tools utilized on the company's premises.
- Phenotypic microfluidic assay
- Drug selection test for cancer patients
- Refrigerant recovery, recycle, recharge machine
- Contact us in order to access
Ramping up production
Indicates the company's current production trend and growth trajectory.
FALSE
Our production algorithm is showing that recurx bio is not ramping up production.
Target industries
Locations (1)
RecurX Bio, Inc
Baltimore, MD, US
Frequently Asked Questions
What services & capabilities does RecurX Bio, Inc offer?
RecurX Bio, Inc offers a range of services and capabilities, including Cancer drugs selection.
What kind of equipment does RecurX Bio, Inc use?
RecurX Bio, Inc uses a variety of equipment, including Phenotypic microfluidic assay.
What are the target industries of RecurX Bio, Inc?
RecurX Bio, Inc serves several industries, including the medical industry.
How many locations does RecurX Bio, Inc operate?
RecurX Bio, Inc operates from a single location at baltimore, maryland, united states.
Where are the headquarters of RecurX Bio, Inc?
The headquarters of RecurX Bio, Inc are located in baltimore, maryland, united states.
What is the NAICS code for RecurX Bio, Inc?
The NAICS code for RecurX Bio, Inc is 3391.
How many employees does RecurX Bio, Inc have?
RecurX Bio, Inc has an employee count in the range of 1-10 employees.
What is the official website of RecurX Bio, Inc?
The official website of RecurX Bio, Inc is https://www.recurxbio.com/.
When was RecurX Bio, Inc founded?
RecurX Bio, Inc was founded in 2020.